Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05367908 · ClinicalTrials.gov registry record
A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind
A clinical trial, sponsored by ModernaTX.
- Completed
- Registry status
- 1,501
- Enrollment target
NCT05367908 is a clinical trial that has completed, run by ModernaTX. The registered enrollment target is 1,501 participants.
The verdict
NCT05367908 has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- 1,501 participants
- Enrollment target
Study Summary
This study will investigate antibody levels with respect to time since receiving a COVID-19 booster shot. The study will be decentralized, where participants can complete all study tasks at home. Self-reported participant information will be collected via surveys conducted at intake and monthly throughout the study. Participants will also perform monthly at-home capillary blood draws via YourBio devices that will be mailed to the designated laboratory for sample processing and antibody testing.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,501 participants |
| Start Date | 2022-04-11 |
| Est. Completion | 2022-08-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05367908
The ClinicalTrials.gov registry entry for NCT05367908 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,501 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05367908 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05367908 about?
NCT05367908 is a clinical study titled "A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind". This study will investigate antibody levels with respect to time since receiving a COVID-19 booster shot. The study will be decentralized, where participants can complete all study tasks at home. Self-reported participant information will be collected via surveys conducted at intake and monthly thro...
What is the current status of trial NCT05367908?
This trial is currently completed. The enrollment target is 1,501 participants. The study started on 2022-04-11. Estimated completion is 2022-08-14.
Who is sponsoring clinical trial NCT05367908?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.